1. Ruthenium Complex Induce Cell Death in G-415 Gallbladder Cancer Cells
- Author
-
Giuliano Bernal, Fabián Cortés-Mancera, Francisco Gajardo, Alvaro Delgadillo, Hernán Villota, and Sebastián Pizarro
- Subjects
Programmed cell death ,chemistry.chemical_element ,Caspase 3 ,Ruthenium ,03 medical and health sciences ,0302 clinical medicine ,In vivo ,Cell Line, Tumor ,Humans ,Medicine ,Gallbladder cancer ,Cytotoxicity ,Cell Proliferation ,Cell Death ,business.industry ,Gastroenterology ,medicine.disease ,In vitro ,Oncology ,chemistry ,Apoptosis ,030220 oncology & carcinogenesis ,Cancer research ,Gallbladder Neoplasms ,030211 gastroenterology & hepatology ,business - Abstract
In this work, we present a recently developed ruthenium complex that shows anticancer activity in gallbladder cancer cells. After the synthesis of the new ruthenium complexes, the antiproliferative, cytotoxicity, and apoptosis activities were evaluated in vitro by the triple assay ApoTox-Glo. Then, the transcription levels of genes related to apoptosis were evaluated by real-time PCR (q-PCR). The ruthenium complex, called Ru-UCN3, inhibits the proliferation of gallbladder cancer cells G-415 by means of apoptosis, which was demonstrated by the overexpression of the pro-apoptotic genes Puma, Diablo, and Caspasa-9 together with the repression of the anti-apoptotic genes Bcl-xL and Bcl-2. In addition, we found strong caspase 3/7 activity in the cells at 24 h of the Ru-UCN3 exposure, which was evaluated by the triple ApoTox-Glo assay. The new ruthenium complexes evaluated had an inhibitory effect on G-415 cells. We think that Ru-UCN3 could be a promising anticancer agent, which should be explored with more in vitro and in vivo assays and probably with the chemical modulation of this molecule.
- Published
- 2019
- Full Text
- View/download PDF